WO2006060809A3 - Procedes d'utilisation de composes heterocycliques [3.2.0] et d'analogues de ces derniers - Google Patents

Procedes d'utilisation de composes heterocycliques [3.2.0] et d'analogues de ces derniers Download PDF

Info

Publication number
WO2006060809A3
WO2006060809A3 PCT/US2005/044091 US2005044091W WO2006060809A3 WO 2006060809 A3 WO2006060809 A3 WO 2006060809A3 US 2005044091 W US2005044091 W US 2005044091W WO 2006060809 A3 WO2006060809 A3 WO 2006060809A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
analogs
heterocyclic compounds
animal
rodent
Prior art date
Application number
PCT/US2005/044091
Other languages
English (en)
Other versions
WO2006060809A9 (fr
WO2006060809A2 (fr
Inventor
Michael Palladino
Barbara Christine Potts
Venkata Rami Reddy Macherla
Saskia Theodora Corn Neuteboom
Original Assignee
Nereus Pharmaceuticals Inc
Michael Palladino
Barbara Christine Potts
Venkata Rami Reddy Macherla
Saskia Theodora Corn Neuteboom
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nereus Pharmaceuticals Inc, Michael Palladino, Barbara Christine Potts, Venkata Rami Reddy Macherla, Saskia Theodora Corn Neuteboom filed Critical Nereus Pharmaceuticals Inc
Priority to AU2005311572A priority Critical patent/AU2005311572A1/en
Priority to CA002590334A priority patent/CA2590334A1/fr
Priority to MX2007006523A priority patent/MX2007006523A/es
Priority to BRPI0517134-2A priority patent/BRPI0517134A2/pt
Priority to EP05853102A priority patent/EP1835910A2/fr
Priority to JP2007544616A priority patent/JP2008522975A/ja
Publication of WO2006060809A2 publication Critical patent/WO2006060809A2/fr
Publication of WO2006060809A3 publication Critical patent/WO2006060809A3/fr
Priority to IL183587A priority patent/IL183587A0/en
Publication of WO2006060809A9 publication Critical patent/WO2006060809A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

L'invention a trait à des méthodes permettant de traiter un cancer, un trouble inflammatoire, et/ou une maladie infectieuse chez un animal. Les méthodes selon l'invention consistent à administrer audit animal une dose thérapeutiquement efficace d'un composé hétérocyclique. Ledit animal est un mammifère, de préférence un être humain ou un rongeur.
PCT/US2005/044091 2004-12-03 2005-12-02 Procedes d'utilisation de composes heterocycliques [3.2.0] et d'analogues de ces derniers WO2006060809A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2005311572A AU2005311572A1 (en) 2004-12-03 2005-12-02 Methods of using (3.2.0) heterocyclic compounds and analogs thereof
CA002590334A CA2590334A1 (fr) 2004-12-03 2005-12-02 Procedes d'utilisation de composes heterocycliques [3.2.0] et d'analogues de ces derniers
MX2007006523A MX2007006523A (es) 2004-12-03 2005-12-02 Metodos para utilizar compuestos heterociclicos [3.2.0] y sus analogos.
BRPI0517134-2A BRPI0517134A2 (pt) 2004-12-03 2005-12-02 métodos de uso de compostos heterocìclicos [ 3.2.0 ] e seus análogos
EP05853102A EP1835910A2 (fr) 2004-12-03 2005-12-02 Procedes d'utilisation de composes heterocycliques [3.2.0] et d'analogues de ces derniers
JP2007544616A JP2008522975A (ja) 2004-12-03 2005-12-02 ［３．２．０］複素環式化合物及びそれらのアナログを使用する方法
IL183587A IL183587A0 (en) 2004-12-03 2007-05-31 Methods of using [3.2.0] heterocyclic compounds and analogs thereof

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US63337904P 2004-12-03 2004-12-03
US60/633,379 2004-12-03
US64392205P 2005-01-13 2005-01-13
US60/643,922 2005-01-13
US65888405P 2005-03-04 2005-03-04
US60/658,884 2005-03-04
US67653305P 2005-04-29 2005-04-29
US60/676,533 2005-04-29

Publications (3)

Publication Number Publication Date
WO2006060809A2 WO2006060809A2 (fr) 2006-06-08
WO2006060809A3 true WO2006060809A3 (fr) 2006-10-05
WO2006060809A9 WO2006060809A9 (fr) 2008-01-17

Family

ID=36565857

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/044091 WO2006060809A2 (fr) 2004-12-03 2005-12-02 Procedes d'utilisation de composes heterocycliques [3.2.0] et d'analogues de ces derniers

Country Status (9)

Country Link
EP (1) EP1835910A2 (fr)
JP (1) JP2008522975A (fr)
KR (1) KR20070086895A (fr)
AU (1) AU2005311572A1 (fr)
BR (1) BRPI0517134A2 (fr)
CA (1) CA2590334A1 (fr)
IL (1) IL183587A0 (fr)
MX (1) MX2007006523A (fr)
WO (1) WO2006060809A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
CA2565235A1 (fr) 2004-04-30 2006-03-16 Nereus Pharmaceuticals, Inc. Composes heterocycliques [3.2.0] et leurs procedes d'utilisation
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
EP1830838B1 (fr) 2004-12-03 2012-10-03 Dana-Farber Cancer Institute, Inc. Compositions et procedes destines au traitement des maladies neoplastiques
WO2006102557A2 (fr) 2005-03-22 2006-09-28 The President And Fellows Of Harvard College Traitement de troubles lies a la degradation de proteines
AU2007345292B2 (en) 2006-02-14 2013-10-31 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
EP2010168B1 (fr) 2006-02-14 2014-04-16 The President and Fellows of Harvard College Inhibiteurs de l'histone desacetylase
CN101460457B (zh) 2006-04-06 2012-07-18 尼瑞斯药品公司 Salinosporamide a及其类似物的全合成
CA2654540C (fr) 2006-05-03 2017-01-17 President And Fellows Of Harvard College Inhibiteurs d'histone desacetylases et de tubuline desacetylases
WO2007130404A1 (fr) * 2006-05-03 2007-11-15 Nereus Pharmaceuticals, Inc. Procédés d'utilisation de composés hétérocycliques [3.2.0] et d'analogues de ceux-ci pour le traitement du cancer du poumon
US8986971B2 (en) 2006-09-22 2015-03-24 Triphase Research And Development I Corp. Salt formulations for the fermentation of marine microorganisms
WO2008095195A2 (fr) 2007-02-02 2008-08-07 Nereus Pharmaceuticals, Inc. Formulations lyophilisées de salinosporamide a
US20080280968A1 (en) * 2007-05-04 2008-11-13 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
EP2088205A1 (fr) 2008-02-11 2009-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) PSMB10 : marqueur de diagnostic et cible thérapeutique de rejet chronique
MX2010009860A (es) 2008-03-07 2010-09-30 Nereus Pharmaceuticals Inc Sintesis total de salinosporamida a y sus analogos.
BRPI0912234A2 (pt) 2008-05-12 2015-10-06 Nereus Pharmaceuticals Inc derivados de salinosporamida como inibidores de proteassomas
RU2515611C2 (ru) 2008-07-23 2014-05-20 Президент Энд Феллоуз Оф Гарвард Колледж Ингибиторы деацетилазы и их применение
WO2011019393A2 (fr) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Inhibiteurs de hdac classe- et isoforme-spécifiques et utilisations de ceux-ci
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996032105A1 (fr) * 1995-04-12 1996-10-17 President And Fellows Of Harvard College Analogues de lactacystine
WO2004043374A2 (fr) * 2002-11-06 2004-05-27 Dana-Farber Cancer Institute, Inc. Procedes et compositions de traitement du cancer au moyen d'inhibiteurs de la proteasome
WO2004071382A2 (fr) * 2003-02-14 2004-08-26 Bayer Healthcare Ag Heterocycles substitues
WO2005002572A2 (fr) * 2003-06-20 2005-01-13 Nereus Pharmaceuticals, Inc. Methodes d'utilisation de composes [3.2.0] heterocycliques et d'analogues correspondants
WO2006028525A2 (fr) * 2004-04-30 2006-03-16 Nereus Pharmaceuticals, Inc. Composes heterocycliques [3.2.0] et leurs procedes d'utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2402045T3 (es) * 2000-11-16 2013-04-26 The Regents Of The University Of California Taxón de actionomiceto marino para el descubrimiento de fármacos y de productos de fermentación
US7176232B2 (en) * 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
EP1830838B1 (fr) * 2004-12-03 2012-10-03 Dana-Farber Cancer Institute, Inc. Compositions et procedes destines au traitement des maladies neoplastiques

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996032105A1 (fr) * 1995-04-12 1996-10-17 President And Fellows Of Harvard College Analogues de lactacystine
WO2004043374A2 (fr) * 2002-11-06 2004-05-27 Dana-Farber Cancer Institute, Inc. Procedes et compositions de traitement du cancer au moyen d'inhibiteurs de la proteasome
WO2004071382A2 (fr) * 2003-02-14 2004-08-26 Bayer Healthcare Ag Heterocycles substitues
WO2005002572A2 (fr) * 2003-06-20 2005-01-13 Nereus Pharmaceuticals, Inc. Methodes d'utilisation de composes [3.2.0] heterocycliques et d'analogues correspondants
WO2006028525A2 (fr) * 2004-04-30 2006-03-16 Nereus Pharmaceuticals, Inc. Composes heterocycliques [3.2.0] et leurs procedes d'utilisation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ELLIOTT P J ET AL: "The proteasome: A new target for novel drug therapies", AMERICAN JOURNAL OF CLINICAL PATHOLOGY, PHILADELPHIA, PA, US, vol. 116, no. 5, November 2001 (2001-11-01), pages 637 - 646, XP008007324, ISSN: 0002-9173 *
TAUCHI ET AL: "Molecular mechanisms of resistance of leukemia to imatinib mesylate", LEUKEMIA RESEARCH, NEW YORK,NY, US, vol. 28, May 2004 (2004-05-01), pages 39 - 45, XP005157790, ISSN: 0145-2126 *
WILLIAMS P G ET AL: "New cytotoxic salinosporamides from the marine actinomycete Salinispora tropica", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 70, no. 16, 1 July 2005 (2005-07-01), pages 6196 - 6203, XP002376431, ISSN: 0022-3263 *

Also Published As

Publication number Publication date
WO2006060809A9 (fr) 2008-01-17
MX2007006523A (es) 2007-09-11
KR20070086895A (ko) 2007-08-27
BRPI0517134A2 (pt) 2011-10-11
IL183587A0 (en) 2008-04-13
WO2006060809A2 (fr) 2006-06-08
JP2008522975A (ja) 2008-07-03
EP1835910A2 (fr) 2007-09-26
AU2005311572A1 (en) 2006-06-08
CA2590334A1 (fr) 2006-06-08

Similar Documents

Publication Publication Date Title
WO2006060809A3 (fr) Procedes d&#39;utilisation de composes heterocycliques [3.2.0] et d&#39;analogues de ces derniers
IL172705A0 (en) Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases
CY1118651T1 (el) Αζακυκλικες ενωσεις για χρηση στην θεραπευτικη αντιμετωπιση ασθενειων που σχετιζονται με τη σεροτονινη
WO2008137780A3 (fr) Procédés d&#39;utilisation de composés [3.2.0]-hétérocycliques et leurs analogues pour traiter des maladies infectieuses
WO2007044085A3 (fr) Composes heteroaryle et leurs utilisations en tant qu&#39;agents therapeutiques
EA200601799A1 (ru) Гидразидсодержащие соединения - ингибиторы cftr и их применение
WO2007046868A3 (fr) Derives de thiazolidine et leurs utilisations en tant qu’agents therapeutiques
WO2007046867A3 (fr) Derives de piperidine et leurs utilisations comme agents therapeutiques
LTC1620113I2 (lt) Ivermektino topinė kompozicija, skirta dermatologinių susirgimų gydymui
WO2007130075A8 (fr) Derives aminothiazole utilises en tant qu&#39;inhibiteurs de la stearoyle-coa desaturase humaine
EP1834637A4 (fr) Preparation prophylactique/therapeutique contre une maladie due aux radicaux libres
TR200901979T2 (tr) Antikolinerjik etkili bileşik ve ?-mimetikler bazında yeni ilaç bileşimleri.
CY1111433T1 (el) Φαρμακευτικο τυποποιημενο παρασκευασμα δεσιταβινης
EP1040831A3 (fr) Utilisation d&#39;antagonistes du facteur de libération de la corticotropine pour la prévention de la mort subite
AU2003239568A1 (en) Pyrrolotriazinone compounds and their use to treat diseases
WO2006081431A3 (fr) Composes utiles dans le traitement des maladies auto-immunes et des troubles de demyelinisation
EA200702387A1 (ru) Имидазохинолины в качестве ингибиторов липидкиназы
WO2008073670A3 (fr) Formulations de doses unitaires et procédés de traitement d&#39;une thrombose avec un inhibiteur oral du facteur xa
BRPI0411241A (pt) agentes terapêuticos úteis para o tratamento de dor
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
WO2002085861A8 (fr) Composes d&#39;imidazolidine et leur utilisation comme antagonistes de cxcr3
WO2005030753A3 (fr) Agents therapeutiques utiles pour traiter la douleur
WO2006118973A3 (fr) Procedes d&#39;utilisation de composes heterocycliques [3.2.0] et de leurs analogues
WO2006125181A3 (fr) Derives piperidiniques: utilisation comme agents therapeutiques
NO20071798L (no) Dermalt pafore formuleringer for behandling av hudsykdommer i dyr

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200580047746.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 555473

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/006523

Country of ref document: MX

Ref document number: 2590334

Country of ref document: CA

Ref document number: 183587

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2005311572

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007544616

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005853102

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005311572

Country of ref document: AU

Date of ref document: 20051202

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005311572

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020077015201

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 07067129

Country of ref document: CO

WWP Wipo information: published in national office

Ref document number: 2005853102

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0517134

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20070604